MimeCure is developing MC002, an active fragment of the body's mimecan protein formulated for inhalation to deliver the agent directly to the lungs. The therapy is designed to combine reduction of scar formation with activation of the lung's natural repair capacity, and development is initially focused on idiopathic pulmonary fibrosis (IPF) with exploration of applicability to COPD and other fibrotic conditions. The company frames MC002 as a potentially regenerative approach that seeks to repair damaged tissue rather than only slow disease progression. MimeCure plans to complete preclinical studies with current funding and begin preparing for first human trials expected at the end of 2027. The company was founded by Luke van der Koog and Erik Frijlink as a University of Groningen spin-off and collaborates closely with the University Medical Center Groningen.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026